Literature DB >> 15077165

C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth.

Carmen Guerrero1, Susana Martín-Encabo, Alberto Fernández-Medarde, Eugenio Santos.   

Abstract

We showed previously that exogenous overexpression of C3G, a guanine nucleotide releasing factor (GEF) for Rap1 and R-Ras proteins, blocks the focus-forming activity of cotransfected, activated, sis, ras and v-raf oncogenes in NIH 3T3 cells. In this report, we show that C3G also interferes with dbl and R-Ras focus-forming activity and demonstrate that the transformation suppressor ability of C3G maps to its Crk-binding region (SH3-b domain). Using full-length C3G and C3GDeltaCat mutant, lacking catalytic domain, we showed here that overexpression of cotransfected C3G or C3GDeltaCat inhibited oncogenic Hraslys12-mediated phosphorylation of ERK, without altering Ras and Raf-1 kinase activation. We also showed that, overexpressed C3G and C3GdeltaCat inhibited the viability of oncogenic Ras-induced colonies in soft agar, indicating that C3G interferes with the anchorage-independent growth of Ras-transformed cells in a Rap1-independent manner. Consistent with both observations, overexpression of exogenous C3G and C3GDeltaCat also caused downregulation of Ras-induced cyclin A expression. Altogether, our results indicate that C3G interferes with at least two separate aspects of oncogenic transformation - cell cycle progression and loss of contact inhibition - and that these inhibitory effects probably account for its transformation suppressor activity. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077165     DOI: 10.1038/sj.onc.1207622

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  C3G contributes to platelet activation and aggregation by regulating major signaling pathways.

Authors:  Cristina Fernández-Infante; Luis Hernández-Cano; Sara Gutiérrez-Herrero; Sara Ortiz-Rivero; Carlos Guijas; Víctor Martín-Granado; José Ramón González-Porras; Jesús Balsinde; Almudena Porras; Carmen Guerrero
Journal:  Signal Transduct Target Ther       Date:  2020-04-01

2.  C3G overexpression in glomerular epithelial cells during anti-GBM-induced glomerulonephritis.

Authors:  Victoriya A Rufanova; Elias Lianos; Anna Alexanian; Elena Sorokina; Mukut Sharma; Ann McGinty; Andrey Sorokin
Journal:  Kidney Int       Date:  2008-09-10       Impact factor: 10.612

3.  Local cell proliferation in rheumatoid synovial tissue: analysis by cyclin expression.

Authors:  Chikako Takahashi Tohyama; Mitsunori Yamakawa; Akira Murasawa; Kiyoshi Nakazono; Hajime Ishikawa
Journal:  Clin Rheumatol       Date:  2006-03-02       Impact factor: 2.980

4.  ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Authors:  Laura Arias-González; Inmaculada Moreno-Gimeno; Antonio Rubio del Campo; Leticia Serrano-Oviedo; María Llanos Valero; Azucena Esparís-Ogando; Miguel Ángel de la Cruz-Morcillo; Pedro Melgar-Rojas; Jesús García-Cano; Francisco José Cimas; María José Ruiz Hidalgo; Alfonso Prado; Juan Luis Callejas-Valera; Syong Hyun Nam-Cha; José Miguel Giménez-Bachs; Antonio S Salinas-Sánchez; Atanasio Pandiella; Luis del Peso; Ricardo Sánchez-Prieto
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

5.  Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes.

Authors:  Kyle J Gaulton; Cristen J Willer; Yun Li; Laura J Scott; Karen N Conneely; Anne U Jackson; William L Duren; Peter S Chines; Narisu Narisu; Lori L Bonnycastle; Jingchun Luo; Maurine Tong; Andrew G Sprau; Elizabeth W Pugh; Kimberly F Doheny; Timo T Valle; Gonçalo R Abecasis; Jaakko Tuomilehto; Richard N Bergman; Francis S Collins; Michael Boehnke; Karen L Mohlke
Journal:  Diabetes       Date:  2008-08-04       Impact factor: 9.461

6.  FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Authors:  Anna Virgili; Diana Brazma; Alistair G Reid; Julie Howard-Reeves; Mikel Valgañón; Anastasios Chanalaris; Valeria As De Melo; David Marin; Jane F Apperley; Colin Grace; Ellie P Nacheva
Journal:  Mol Cytogenet       Date:  2008-07-18       Impact factor: 2.009

7.  C3G knock-down enhances migration and invasion by increasing Rap1-mediated p38α activation, while it impairs tumor growth through p38α-independent mechanisms.

Authors:  Neibla Priego; María Arechederra; Celia Sequera; Paloma Bragado; Ana Vázquez-Carballo; Álvaro Gutiérrez-Uzquiza; Víctor Martín-Granado; Juan José Ventura; Marcelo G Kazanietz; Carmen Guerrero; Almudena Porras
Journal:  Oncotarget       Date:  2016-07-19

8.  C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.

Authors:  Víctor Martín-Granado; Sara Ortiz-Rivero; Rita Carmona; Sara Gutiérrez-Herrero; Mario Barrera; Laura San-Segundo; Celia Sequera; Pedro Perdiguero; Francisco Lozano; Francisco Martín-Herrero; José Ramón González-Porras; Ramón Muñoz-Chápuli; Almudena Porras; Carmen Guerrero
Journal:  Oncotarget       Date:  2017-11-06

Review 9.  How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma.

Authors:  Celia Sequera; Sara Manzano; Carmen Guerrero; Almudena Porras
Journal:  Hepat Oncol       Date:  2018-04-16

10.  C3G contributes to platelet activation and aggregation by regulating major signaling pathways.

Authors:  Cristina Fernández-Infante; Luis Hernández-Cano; Sara Gutiérrez-Herrero; Sara Ortiz-Rivero; Carlos Guijas; Víctor Martín-Granado; José Ramón González-Porras; Jesús Balsinde; Almudena Porras; Carmen Guerrero
Journal:  Signal Transduct Target Ther       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.